Please use this identifier to cite or link to this item:
|Title:||Sugar-lowering drugs for type 2 diabetes mellitus and metabolic syndromestrategies for in vivo administration: Part-II|
Souto, Selma B.
López Machado, Ana
Silva, Amelia M.
García, Maria Luisa
|Publisher:||Multidisciplinary Digital Publishing Institute (MDPI)|
|Journal:||Journal of Clinical Medicine|
|Citation:||Vieira, Raquel; Souto, Selma B.; Sánchez-López, Elena; López Machado, Ana; Severino, Patricia; Jose, Sajan; Santini, Antonello; Silva, Amelia M.; Fortuna, Ana; García, Maria Luisa; Souto, Eliana, Sugar-lowering drugs for type 2 diabetes mellitus and metabolic syndromestrategies for in vivo administration: Part-II. Journal of Clinical Medicine, 8(9), 1332, 2019|
|Abstract(s):||Diabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic ß-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed.|
|Appears in Collections:||CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series|
This item is licensed under a Creative Commons License